News

BGPartner is pleased to welcome Geremia Stüssi (Trainee) to the Zurich team as of March 1, 2022. Further information on Geremia Stüssi and our entire team can be found here.

BGPartner is pleased to welcome Tanja Aebersold to the Berne team as of September 1, 2021. Further information on Tanja Aebersold and our entire team can be found here.

BGPartner advises Memo Therapeutics Ltd on its CHF 37 Million Series B Financing Round

BGPartner advises Memo Therapeutics Ltd, an innovator in the field of antibody discovery and development, on its successfully closing of a CHF 37 million series B financing round following an oversubscribed CHF 23 million extension. BGPartner assisted Memo Therapeutics Ltd in the negotiations and advised on all Swiss legal matters with regard to this transaction.

The strategic and financial investors of this series B financing include Swisscanto (lead investor), Adjuvant Capital, Fresenius Medical Care Ventures, GF Group, Verve Ventures, Vesalius Biocapital and Zürcher Kantonalbank and other investors. The roots of investor Adjuvant Capital date back to efforts by the Bill & Melinda Gates Foundation and J.P. Morgan to test the idea of building an impact investment portfolio from the most promising drug, vaccine, diagnostic, and medical device technologies that address high-burden public health challenges, neglected infectious diseases, and maternal/infant mortality.

Memo Therapeutics Ltd intends to use the proceeds to advance clinical development of its best- and first-in-class neutralizing antibody, MTX-005, targeting BK virus infection in renal transplant patients. In addition, Memo Therapeutics Ltd will use the funding to develop and expand its antibody pipeline and secure new partnering agreements.

Furthermore, Memo Therapeutics Ltd recently announced that it has received a CHF 10.5 million commitment from the Swiss Federal Funding Programme for COVID-19 medicines to advance COVAB 36, a potent, fully human monoclonal antibody administered via inhalation for the treatment of SARS-CoV-2 infections, into clinical development.

The BGPartner team assisting Memo Therapeutics Ltd in legal and negotiation matters is led by Oliver Gnehm (Partner) and further consists of Victoria Marty (Associate) and Thomas Gysin (Senior Associate).

More information about our negotiation expertise can be found here.

BGPartner has been repeatedly awarded as top law firm in the area of "Private Equity and Venture Capital". More information can be found here.

BGPartner advised on one of the largest financing rounds in Switzerland, according to the Swiss Venture Capital Report 2022.

BGPartner is proud to have advised on one of the largest financing rounds in Switzerland: according to the Swiss Venture Capital Report 2022, the CHF 100 million investment in Numab Therapeutics Ltd ranks among the top 20 (rank 5) of the largest financing rounds in 2021.

In this transaction HBM Healthcare Investments Ltd and Novo Holdings A/S, as co-lead-investors, together with other investors including Forbion and Black Rock, successfully closed in 2021 an investment in Numab Therapeutics Ltd’s series C financing round.

Numab Therapeutics Ltd is a clinical stage biopharmaceutical company developing next-generation multi-specific antibody-based immunotherapies for cancer and inflammation.

BGPartner assisted HBM Healthcare Investments Ltd and Novo Holdings A/S in the negotiations and advised them on all Swiss legal matters with regard to this series c financing round. The team was led by Oliver Gnehm (Partner) and further consisted of Olivier Bula (Partner), Victoria Marty (Associate), Thomas Gysin (Senior Associate) and Fabiola Anthamatten (Managing Associate).

BGPartner has been repeatedly awarded as top law firm in the area of "Private Equity and Venture Capital". More information can be found here.

Big news right at the beginning of the year. Juliane Hogrefe becomes a partner at  BGPartner.  
 
The existing partners Michael Bader Oliver Gnehm Elena Mégevand-Valli Kunz Stefan and Olivier Bula congratulate Juliane Hogrefe on this great achievement and are looking forward to continue to grow together.
 
Juliane Hogrefe started as a junior associate at BGPartner in 2012. The fact that she is now a partner at the age of 36 fills her with pride and joy.

During her career, Juliane Hogrefe not only developed into a negotiation specialist, but became an expert in the following practice areas: Construction and Real Estate Law, Intellectual Property Rights, Contract Law, Insolvency Law and Civile Aviation Law.

Juliane Hogrefe can hardly wait to actively shape the future of BGPartner together with the entire team.